Priothera

Executive Summary

Priothera is a clinical-stage Irish biotechnology company developing mocravimod, a first-in-class S1P receptor modulator designed to improve outcomes in allogeneic hematopoietic cell transplantation (allo-HCT) and CAR T-cell therapy for hematological malignancies. By enhancing the graft-versus-leukemia effect while reducing graft-versus-host disease, mocravimod addresses critical unmet needs in transplant medicine. The company has advanced mocravimod into Phase 2 trials for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) post-transplant, and is exploring combinations with CAR T-cell therapies. With a strong mechanistic rationale and early clinical signals, Priothera represents a promising approach to expanding the curative potential of cellular therapies. The company is privately held and based in Dublin, Ireland, with a focused pipeline and potential for significant value inflection as data mature.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for mocravimod in AML post-allo-HCT50% success
• Q2 2026FDA IND clearance for mocravimod + CAR-T combination trial70% success
• Q3 2026Partnership or licensing deal for ex-European rights40% success